PD-1/PD-L1-IN 7 (Synonyms: PD-1/PD-L1-IN 7) |
| Catalog No.GC62658 |
PD-1/PD-L1-IN 7 (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2374856-75-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PD-1/PD-L1-IN 7 is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 has anticancer and antiviral functions[1].
PD-1/PD-L1-IN 7 (compound 139) enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. PD-1/PD-L1-IN 7 also enhances the frequency of GrB+ cells among HBV-specific CD8+ and CD4+ T cells. The ability of PD-1/PD-L1-IN 7 to enhance the antiviral functions of HBV-specific CD8+ and CD4+ T cells in vitro is comparable to those of Durvalumab[1].
PD-1/PD-L1-IN 7 (Compound 139; 10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment shows >90% PD-L1 target occupancy (TO) on the tumor cells. PD-1/PD-L1-IN 7 significantly inhibits tumor growth in a human PD-L1 expressing MC38 mouse colorectal tumor model[1].
[1]. Evangelos Aktoudianakis, et al. Pd-1/pd-l1 inhibitors. WO2019160882A1.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *